What are NK1 receptor antagonist drugs?

NK1 receptor antagonist drugs are pharmacologic agents that share a common mechanism (typically targeting NK1 receptor (neurokinin-1 receptor)). 1 are currently marketed, with 19 more in clinical development.

What are the marketed NK1 receptor antagonist drugs?

Marketed NK1 receptor antagonist drugs include Fosaprepitant for Injection.

NK1 receptor antagonist

1 marketed 17 in Phase 3 2 in Phase 2

This page covers all NK1 receptor antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting NK1 receptor (neurokinin-1 receptor), NK1 receptor.

Targets

NK1 receptor (neurokinin-1 receptor) · NK1 receptor

Marketed (1)

Fosaprepitant for Injection · Montefiore Medical Center · Oncology
Fosaprepitant is an intravenous prodrug that is rapidly converted to aprepitant, a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center.

Phase 3 pipeline (17)

Placebo to MK-0954A · Organon and Co · Oncology; Gastroenterology
MK-0954A is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system.
APD421 · Acacia Pharma Ltd · Oncology / Anesthesia
APD421 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center.
MK0733 / Duration of Treatment: 18 Weeks · Organon and Co · Oncology / Pain Management
MK0733 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system.
Standard: Aprepitant · CCTU · Oncology
Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist.
Emend® (Aprepitant) · CR-CSSS Champlain-Charles-Le Moyne · Oncology
Aprepitant blocks substance P neurokinin-1 (NK1) receptors in the chemoreceptor trigger zone and vomiting center to prevent chemotherapy-induced nausea and vomiting.
MK0869, aprepitant · Merck Sharp & Dohme LLC · Oncology
Aprepitant is a selective antagonist of neurokinin-1 (NK1) receptors that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center of the brain.
Oral Casopitant (GW679769) · GlaxoSmithKline · Oncology
Casopitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center to prevent chemotherapy-induced nausea and vomiting.
Experimental drug: Aprepitant · CCTU · Oncology / Supportive Care
Aprepitant blocks neurokinin-1 (NK1) receptors in the brain to prevent nausea and vomiting.
GW679769 (casopitant) · GlaxoSmithKline · Oncology
Casopitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the brain to prevent chemotherapy-induced nausea and vomiting.
saredutant (SR48968) · Sanofi · Oncology
Saredutant is an antagonist of the neurokinin-1 (NK1) receptor.
Comparator: fosaprepitant dimeglumine · Merck Sharp & Dohme LLC · Oncology
Fosaprepitant dimeglumine is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center to prevent chemotherapy-induced nausea and vomiting.
placebo to aprepitant · Merck Sharp & Dohme LLC · Oncology
Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist.
MK-1084 · Merck Sharp & Dohme LLC · Pain management / Oncology supportive care
MK-1084 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system.
OPC-61815 injection · Otsuka Pharmaceutical Co., Ltd. · Oncology / Supportive Care
OPC-61815 is a selective antagonist of the neurokinin-1 (NK1) receptor that reduces substance P signaling in the central nervous system.
MK-0954A · Organon and Co · Oncology; Pain Management
MK-0954A is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system.
NOVA22007 · Santen SAS · Ophthalmology
NOVA22007 is a selective antagonist of the neurokinin-1 (NK1) receptor that reduces neurogenic inflammation and pain signaling in the eye.
IV Casopitant (GW679769) · GlaxoSmithKline · Oncology
Casopitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center to prevent chemotherapy-induced nausea and vomiting.

Phase 2 pipeline (2)

APD515 · Acacia Pharma Ltd · Oncology / Gastroenterology
APD515 is a selective antagonist of the neurokinin-1 (NK1) receptor that reduces nausea and vomiting by blocking substance P signaling in the chemoreceptor trigger zone and vomiting center.
Aprepitant vs. Gabapentin · New Mexico Cancer Research Alliance · Oncology
Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist, which blocks the action of substance P, a natural substance in the body that causes nausea and vomiting.